文献速递其他结缔组织病血管炎

三联疗法对灾难性抗磷脂综合征患者死亡率的影响

The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

基于CAPS注册队列纳入471例灾难性抗磷脂综合征患者,按是否接受三联疗法(抗凝+糖皮质激素+血浆置换和/或静脉注射免疫球蛋白)分组,比较全因死亡率。三联疗法组死亡率28.6%,其他联合用药组41.1%,未治疗组75%;三联疗法与更高生存率独立相关。

要点

  • 三联疗法组死亡率28.6%,其他联合用药组41.1%,未治疗组75%。
  • 与未治疗相比,三联疗法与更高生存机会相关(调整OR=9.7,95%CI:2.3,40.6)。
  • 三联疗法中含血浆置换或IVIG的患者间无统计学差异(P=0.92)。

核心结论

  • 三联疗法与灾难性抗磷脂综合征患者更高的生存率独立相关。

研究设计与样本

  • 基于CAPS注册队列,纳入471例灾难性抗磷脂综合征患者,按三联疗法、三联疗法中药物其他组合、未接受三联疗法中任何治疗分组,采用多因素logistic回归比较全因死亡率。

主要发现

  • 总体174例(36.9%)患者死亡。
  • 三联疗法组死亡率28.6%,其他联合用药组41.1%,未治疗组75%。
  • 与未治疗相比,三联疗法与更高生存机会相关(调整OR=9.7,95%CI:2.3,40.6)。
  • 与其他联合用药相比,三联疗法与更高生存机会相关(调整OR=1.7,95%CI:1.2,2.6)。
  • 三联疗法中含血浆置换或IVIG的患者间无统计学差异(P=0.92)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to assess the effect that triple therapy (anticoagulation plus CS plus plasma exchange and/or IVIGs) has on the mortality risk of patients with catastrophic APS (CAPS) included in the CAPS Registry. METHODS: Patients from the CAPS Registry were grouped based on their treatments: triple therapy; drugs included in the triple therapy but in different combinations; and none of the treatments included in the triple therapy. The primary endpoint was all-cause mortality. Multivariate logistic regression models were used to compare mortality risk between groups. RESULTS: The CAPS Registry cohort included 525 episodes of CAPS accounting for 502 patients. After excluding 54 episodes (10.3%), a total of 471 patients with CAPS were included [mean (s.d.) age 38.5 years (17); 68.2% female; primary APS patients 62%]. Overall, 174 (36.9%) patients died. Triple therapy was prescribed in 189 episodes (40.1%), other combinations in 270 (57.3%) and none of those treatments in 12 episodes (2.5%); the mortality rate in the three groups was 28.6, 41.1 and 75%, respectively. Triple therapy was positively associated with a higher chance of survival when compared with non-treatment [adjusted odds ratio (OR) = 9.7, 95% CI: 2.3, 40.6] or treatment with other combinations of drugs included in the triple therapy (adjusted OR = 1.7, 95% CI: 1.2, 2.6). No statistical differences were found between patients that received triple therapy with plasma exchange or IVIGs (P = 0.92). CONCLUSION: Triple therapy is independently associated with a higher survival rate among patients with CAPS.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Rodríguez-Pintó I, Espinosa G, Erkan D, et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients. Rheumatology (Oxford). 2018. PMID: 29660074. doi:10.1093/rheumatology/key082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。